PL3377534T3 - Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4 - Google Patents

Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4

Info

Publication number
PL3377534T3
PL3377534T3 PL16819718.4T PL16819718T PL3377534T3 PL 3377534 T3 PL3377534 T3 PL 3377534T3 PL 16819718 T PL16819718 T PL 16819718T PL 3377534 T3 PL3377534 T3 PL 3377534T3
Authority
PL
Poland
Prior art keywords
antibody
ctla
treatment
combination
lung cancer
Prior art date
Application number
PL16819718.4T
Other languages
English (en)
Inventor
Nathan E. FAITH
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57680484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3377534(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3377534T3 publication Critical patent/PL3377534T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL16819718.4T 2015-11-18 2016-11-18 Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4 PL3377534T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257139P 2015-11-18 2015-11-18
US201662345314P 2016-06-03 2016-06-03
PCT/US2016/062884 WO2017087870A1 (en) 2015-11-18 2016-11-18 Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
PL3377534T3 true PL3377534T3 (pl) 2025-09-01

Family

ID=57680484

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819718.4T PL3377534T3 (pl) 2015-11-18 2016-11-18 Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4

Country Status (18)

Country Link
US (3) US11072657B2 (pl)
EP (2) EP4609915A3 (pl)
JP (3) JP2018538263A (pl)
KR (2) KR20180071386A (pl)
CN (2) CN108350081A (pl)
DK (1) DK3377534T3 (pl)
ES (1) ES3034582T3 (pl)
FI (1) FI3377534T3 (pl)
HR (1) HRP20250902T1 (pl)
HU (1) HUE072729T2 (pl)
LT (1) LT3377534T (pl)
PL (1) PL3377534T3 (pl)
PT (1) PT3377534T (pl)
RS (1) RS67037B1 (pl)
SI (1) SI3377534T1 (pl)
SM (1) SMT202500282T1 (pl)
TW (4) TWI912619B (pl)
WO (1) WO2017087870A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
US11072657B2 (en) 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
KR102634093B1 (ko) * 2016-10-28 2024-02-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
EP3707164A4 (en) * 2017-11-07 2021-11-24 Memorial Sloan-Kettering Cancer Center INHIBITION OF CTLA-4 AND / OR PD-1 FOR THE REGULATION OF T-LYMPHOCYTES
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
MA55316A (fr) * 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020198676A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
US12655219B2 (en) 2020-07-21 2026-06-16 Shanghai Junshi Biosciences Co., Ltd. Anti-CTLA-4 antibody and use thereof
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
LT4243928T (lt) 2020-11-10 2026-06-10 Catalym Gmbh Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui
US20220267446A1 (en) * 2021-02-18 2022-08-25 Qilu Puget Sound Biotherapeutics Corporation Combinations of anti-pd1 and anti-ctla4 antibodies
US20250376525A1 (en) * 2022-06-28 2025-12-11 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8435516B2 (en) * 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2013296919A1 (en) * 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
KR20160079114A (ko) * 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
EP3288980B1 (en) * 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
EP3288565A4 (en) * 2015-04-30 2019-02-13 Histogen, Inc. EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER OR IMMUNE DISEASES
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
DK3858859T3 (da) * 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
US11072657B2 (en) 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
EP3408296A1 (en) 2016-01-27 2018-12-05 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
MA44483A (fr) * 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
KR20250107295A (ko) 2016-06-03 2025-07-11 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
JP2022505647A (ja) * 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法

Also Published As

Publication number Publication date
CN108350081A (zh) 2018-07-31
SI3377534T1 (sl) 2025-09-30
EP4609915A3 (en) 2025-11-19
EP3377534B1 (en) 2025-06-18
JP2018538263A (ja) 2018-12-27
HRP20250902T1 (hr) 2025-09-26
SMT202500282T1 (it) 2025-09-12
JP2025029025A (ja) 2025-03-05
JP2022068352A (ja) 2022-05-09
TW201731527A (zh) 2017-09-16
PT3377534T (pt) 2025-07-10
TWI821748B (zh) 2023-11-11
HUE072729T2 (hu) 2025-12-28
US20220017619A1 (en) 2022-01-20
TW202604568A (zh) 2026-02-01
US20250154257A1 (en) 2025-05-15
KR20260020215A (ko) 2026-02-10
FI3377534T3 (fi) 2025-08-22
TWI912619B (zh) 2026-01-21
US20180371092A1 (en) 2018-12-27
EP4609915A2 (en) 2025-09-03
TWI795347B (zh) 2023-03-11
LT3377534T (lt) 2025-08-11
US12528865B2 (en) 2026-01-20
TW202408573A (zh) 2024-03-01
EP3377534A1 (en) 2018-09-26
US11072657B2 (en) 2021-07-27
KR20180071386A (ko) 2018-06-27
DK3377534T3 (da) 2025-08-18
CN122140919A (zh) 2026-06-05
ES3034582T3 (en) 2025-08-20
WO2017087870A1 (en) 2017-05-26
RS67037B1 (sr) 2025-08-29
TW202227132A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
PT3377534T (pt) Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4
IL282962A (en) Anti-PD-1 antibodies and methods of using them
IL268479A (en) Anti-PD-1 antibodies for the treatment of lung cancer
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL276481B (en) Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer
IL262892A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
IL259924A (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL252280A0 (en) Anti pd-1 antibodies and methods of using them
SG10201913500TA (en) Anti-ctla-4 antibodies and methods of use thereof
IL259713B2 (en) Anti-DR5 antibodies and methods of using them
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
IL307850A (en) A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
IL266990A (en) Methods for treating cancer using anti-pd-l1 antibodies and antiandrogens
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
HK40018984A (en) Anti-pd-1 antibodies for treatment of lung cancer
GB201604293D0 (en) Treatment of cancer